Alpha-L-Iduronidase (Laronidase; Aldurazyme)
Recombinant human α-L-iduronidase (laronidase; Aldurazyme BioMarin/Genzyme), an orphan drug, has been approved by the FDA for enzyme replacement therapy in mucopolysaccharidosis (MPS) type I, a lysosomal storage disorder caused by deficiency of the enzyme. This review describes the disease, treatment, adverse effects and cost....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Alpha-L-Iduronidase (Laronidase; Aldurazyme)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1168
Article Code: 1168c
Date: October 27, 2003
Volume: 45
Page: 88
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1168
Article Code: 1168c
Date: October 27, 2003
Volume: 45
Page: 88
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)